БЛОГ

Archive for the ‘biotech/medical’ category: Page 568

Jul 7, 2023

Could regenerating the thymus boost human longevity?

Posted by in categories: biotech/medical, life extension

DISCLOSURE: Longevity. Technology (a brand of First Longevity Limited) has been contracted by the company featured in this article to support its current funding round. Qualifying investors can find out more via the Longevity. Technology investor portal.

British regenerative medicine company Videregen is on a mission to cure chronic diseases and is targeting the human immune system through its work to regenerate the thymus. Building on groundbreaking work conducted at the Francis Crick Institute, Videregen believes its technology holds the potential to restore the function of the aging immune system. The company is already approved for initial clinical trials of its technology in respiratory disease and is working towards trials of its regenerative thymus technology within three years.

Longevity Technology: The thymus is a small but important organ in the immune system and is responsible for the development and maturation of critical T cells. It plays a key role in our early development, but declines significantly as we age, along with the functionality of our immune system, and its decline is linked to several age-related and chronic diseases. Videregen is betting that its technology can help restore the thymus, potentially rejuvenating our immune system in the process. To learn more, we spoke to the company’s CEO, Dr Steve Bloor.

Jul 7, 2023

New regenerative stem cell therapy for heart disease shows promise

Posted by in categories: biotech/medical, life extension

A stem cell therapy treatment developed by Duke-NUS Medical School researchers for heart failure has shown promising results in preclinical trials. These cells, when transplanted into an injured heart, are able to repair damaged tissue and improve heart function, according to a study published in the journal npj Regenerative Medicine.

Longevity. Technology: The most common cause of death worldwide is ischemic heart disease, which is caused by diminished blood flow to the heart. When blood flow to the heart is blocked, the heart muscle cells die – a condition termed myocardial infarction or heart attack, something that happens to 805,000 people a year in the US [1].

In the Duke-NUS study, a unique new protocol was used where pluripotent stem cells were cultivated in the laboratory in order to grow into heart muscle precursor cells – these cardiomyocyte progenitors can develop into various types of heart cells, through a process called cell differentiation in which dividing cells gain specialised functions. During preclinical trials, the precursor cells were injected into the area of the heart damaged by myocardial infarction, where they were able to grow into new heart muscle cells, restoring damaged tissue and improving heart function.

Jul 7, 2023

Doctor AI Will See You Now

Posted by in categories: biotech/medical, health, robotics/AI

Tanya Lewis: Hi, and welcome to Your Health, Quickly, a Scientific American podcast series!

Jul 7, 2023

New Bacterial Structure Helps Overcome Antibiotic Resistance

Posted by in category: biotech/medical

May people worry that infectious pathogens will become resistant to current first-line therapies like antibiotics. Bacteria and other infectious diseases evolve and change to meet the needs of their environment and overcome treatments like these. Cancer is a well-known case in which the tumor cells evolve and become resistant to immunotherapy and other targeted treatments. Cancer is a prime example, because it rapidly divides and the mechanism by which it progresses allows tumor cells to avoid or overcome therapies. However, bacterial diseases are also common infections that can rapidly evolve. The World Health Organization (WHO) has even warned against a time in which antibiotics will not work. If this were the case, minor illnesses such as the common cold, could become fatal. The worry of antibiotic resistance is partly the reason we get yearly vaccinations. The Center for Disease Control (CDC) best predicts which viral infections will persist in the following year. A multitude of data is included in this prediction including the following:

Jul 7, 2023

Tamiflu for preventing flu admissions

Posted by in category: biotech/medical

Influenza, or the “flu,” is a viral respiratory infection that commonly affects the nose, throat, and lungs. Some symptoms of flu infection include fever, muscle ache, headache, dry cough, shortness of breath, general malaise, and more. Most healthy people with active flu infections can fight off the infection with their immune systems, however, certain high-risk groups may be prone to developing complications, such as children under 2 years old, adults over 65 years old, those that are pregnant, those with weakened immune systems, those with chronic illnesses, and those with a body mass index of 40 or higher.

The influenza vaccine is a preventative vaccine that reduces the chances of a patient having severe complications from the virus. Even after preventative measures such as the influenza vaccine, some adults remain at high risk for hospitalization following an infection. That is where flu antiviral drugs come in; antiviral drugs are medications that assist your body in fighting viruses.

The most common antiviral for the flu is Tamiflu, generically known as oseltamivir. Oseltamivir is a neuraminidase inhibitor and was approved by the United States Food and Drug Administration in 1999. When oseltamivir is started within two days of flu symptoms and confirmed flu infection, it can shorten length of illness along with a decrease in overall symptoms. This is especially useful in high-risk populations who may be able to prevent a hospitalization after taking oseltamivir.

Jul 7, 2023

Evaluation of Oseltamivir to Prevent Hospitalization in Outpatients With Influenza

Posted by in category: biotech/medical

Importance Despite widespread use, summary evidence from prior meta-analyses has contradictory conclusions regarding whether oseltamivir decreases the risk of hospitalization when given to outpatients. Several large investigator-initiated randomized clinical trials have not yet been meta-analyzed.

Objective To assess the efficacy and safety of oseltamivir in preventing hospitalization among influenza-infected adult and adolescent outpatients.

Jul 7, 2023

Profound Paradigm Shift in Cellular Biology — DNA Damage Repaired by Antioxidant Enzymes

Posted by in category: biotech/medical

In crisis, the nucleus calls antioxidant enzymes to the rescue. The nucleus being metabolically active is a profound paradigm shift with implications for cancer research.

Jul 7, 2023

Threads, Twitter and Mark Zuckerberg’s long history of copycat apps and features

Posted by in categories: biotech/medical, innovation

Mark Zuckerberg isn’t particularly shy about copying a good idea when he sees one.

From cribbing Snapchat’s stories feature to cloning TikTok in the form of Instagram Reels, the Facebook co-founder has a long and well-documented history of being a copycat.

Zuckerberg’s latest not-quite-innovation comes in the form of Threads, an Instagram-based Twitter competitor.

Jul 7, 2023

23-YO Brews Up Startup Success With Hot Chocolate That Empowers Organic Farmers

Posted by in categories: biotech/medical, sustainability

Anuva Kakkar, the 23-year-old entrepreneur behind Tiggle, an Agra-based D2C organic hot chocolate brand, has come a long way in a very short period despite the ongoing COVID-19 pandemic. From selling cups of hot chocolate to commuters outside the DLF Phase-3 metro station in Gurugram to starting her brand of hot chocolate powder and selling over 2 lakh cups through 2021, it has been a mercurial rise.

Made of premium cocoa sourced from a 40-acre family-owned certified organic farm near Pollachi, Tamil Nadu, Tiggle today sells three ‘premium’ varieties of hot chocolate powder — Light Hot Chocolate Mix, Dark Hot Chocolate Mix and Jaggery Hot Chocolate Mix. So, how did this entrepreneur from Agra set up her venture in such a challenging time for commerce?

Jul 6, 2023

Chromosome Imbalances Drive Cancer, And Removing Extras Can Stop It

Posted by in categories: biotech/medical, computing

Many cancer cells carry too many or too few chromosomes, a condition known as aneuploidy. Scientists have known this for a very long time, but the impact of aneuploidy has been unclear. Researchers recently developed a computational tool that analyzed cells from thousands of cancer patients. This effort identified critical regions of chromosomes that can be harmful or beneficial to tumor cells when they are deleted or duplicated. The findings have been reported in Nature.

In this study, the investigators developed a method called BISCUT (Breakpoint Identification of Significant Cancer Undiscovered Targets), which located where major changes start and end in chromosomes. Regions that were often found were more likely to help cancer cells survive while less commonly found regions were associated with a lack of cancer cell growth or their death. For example, one-third of all cancer cells in The Cancer Cell Genome Atlas lack one arm of chromosome 8.

Page 568 of 2,734First565566567568569570571572Last